In silico and in vivo neuropharmacological evaluation of two γ-amino acid isomers derived from 2,3-disubstituted benzofurans, as ligands of GluN1-GluN2A NMDA receptor
- PMID: 34854957
- DOI: 10.1007/s00726-021-03108-2
In silico and in vivo neuropharmacological evaluation of two γ-amino acid isomers derived from 2,3-disubstituted benzofurans, as ligands of GluN1-GluN2A NMDA receptor
Abstract
The GABAergic and glutamatergic neurotransmission systems are involved in seizures and other disorders of the central nervous system (CNS). Benzofuran derivatives often serve as the core in drugs used to treat such neurological disorders. The aim of this study was to synthesize new γ-amino acids structurally related to GABA and derived from 2,3-disubstituted benzofurans, analyze in silico their potential toxicity, ADME properties, and affinity for the GluN1-GluN2A NMDA receptor, and evaluate their potential activity and neuronal mechanisms in a murine model of pentylenetetrazol (PTZ)- and 4-aminopyridine (4-AP)-induced seizures. The in silico analysis evidenced a low risk of toxicity for the test compounds as well as the probability that they can cross the blood-brain barrier (BBB) to reach their targets in the CNS. According to docking simulations, these compounds bind at the active site of the NMDA glutamate receptor with high affinity. The in vivo assays demonstrated that 4 protects against 4-AP-induced seizure episodes, suggesting negative allosteric modulation (NAMs) at the glutamatergic NMDA receptor. Contrarily, 3 (the regioisomer of 4) and its racemic derivatives (cis-2,3-dihydrobenzofurans) were previously described to exacerbate such episodes, pointing to their positive allosteric modulation (PAMs) of the same receptor.
Keywords: 2,3-Disubstituted benzofurans; 4-Aminopyridine (4-AP); NMDA receptor; Pentylenetetrazol (PTZ).
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
References
-
- Akyuz E, Paudel YN, Polat AK et al (2021) Enlightening the neuroprotective effect of quercetin in epilepsy: from mechanism to therapeutic opportunities. Epilepsy Behav 115:107701–107709. https://doi.org/10.1016/j.yebeh.2020.107701 - DOI - PubMed
-
- Alexander SP, Peters JA, Kelly E et al (2017) The concise guide to pharmacology 2017/18: ligand-gated ion channels. Br J Pharmacol 174:S130–S159. https://doi.org/10.1111/bph.13879 - DOI - PubMed - PMC
-
- Baragona F, Lomberget T, Duchamp C et al (2011) Synthesis of 5-substituted 2,3-dihydrobenzofurans in a one-pot oxidation/cyclization reaction. Tetrahedron 67:8731–8739. https://doi.org/10.1016/j.tet.2011.09.020 - DOI
-
- Bergmann R, Kongsbak K, Sørensen PL et al (2013) A unified model of the GABAA receptor comprising agonist and benzodiazepine binding sites. PLoS One 8:e52323. https://doi.org/10.1371/journal.pone.0052323 - DOI - PubMed - PMC
-
- Bhagat K, Singh JV, Pagare PP et al (2020) Rational approaches for the design of various GABA modulators and their clinical progression. Mol Divers. https://doi.org/10.1007/s11030-020-10068-4 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources